Hydrogel microsphere stem cell encapsulation enhances cardiomyocyte differentiation and functionality in scalable...

Area of Science:

• Biotechnology
• Regenerative Medicine
• Stem Cell Biology

Background:

• Scalable production of engineered cardiac tissues (ECTs) from human induced pluripotent stem cells (hiPSCs) is essential for regenerative therapies.
• Current scaffold-free aggregate platforms face challenges in consistency and functionality for large-scale ECT manufacturing.

Purpose of the Study:

• To compare a novel scaffold-based microsphere platform with the prevalent scaffold-free aggregate platform for hiPSC-derived ECT production.
• To evaluate the scalability, consistency, and functional performance of ECTs generated by both platforms.

Main Methods:

• Utilized a microfluidic system for high-density encapsulation of hiPSCs within PEG-fibrinogen hydrogel microspheres.
• Compared suspension-based cardiac differentiation of microspheres and aggregates in chemically defined media.
• Assessed tissue size, shape, cardiomyocyte content, contractile function, and gene expression.

Main Results:

• Microspheres exhibited significantly higher consistency in size and shape compared to aggregates.
• Microsphere platform yielded 27% higher cardiomyocyte content and 250% higher cardiomyocyte yield per hiPSC.
• Microspheres demonstrated 4-9 times higher contraction and relaxation velocities, improved functionality over time, and enhanced signaling responsiveness.

Conclusions:

• The scaffold-based microsphere platform offers a scalable and robust solution for biomanufacturing of engineered cardiac tissues.
• This platform demonstrates superior consistency and functional performance over scaffold-free aggregate methods for cardiac regeneration applications.